LEO Pharma Delivers 10% Revenue Growth in 2025 and More Than Doubles Adjusted EBITDA Margin
BALLERUP, Denmark--(BUSINESS WIRE)--Feb 18, 2026-- In 2025, LEO Pharma delivered a third consecutive year of double‑digit revenue growth (CER), at the upper end of guidance, and achieved a significant improvement in profitability, returning to positive net …